Table 3.

Biomarkers in patients with clinical cure and clinical failure

	Clinical cure	Clinical failure	P value
All patients (n = 249)	n = 229	n = 20
At presentation
PCT	0.40 (0.13–1.54)	0.36 (0.10–1.46)	0.749
PCT > 0.25	136 (59%)	12 (60%)	0.957
CRP	120 (53–211)	90 (27–223)	0.851
proADM	0.89 (0.62–1.30)	0.86 (0.67–1.20)	0.948
Day 3
PCT	0.18 (0.07–0.87)	0.12 (0.04–0.69)	0.667
PCT ≤ 0.25	122 (60%)	12 (67%)	0.568
PCT ≤ 0.25 or PCT decline ≥80%	144 (71%)	14 (78%)	0.519
proADM	0.66 (0.50–0.91)	0.63 (0.51–0.78)	0.667
Short treatment (n = 92)	n = 82	n = 10
At presentation
PCT	0.34 (0.10–1.68)	0.36 (0.11–1.79)	0.980
PCT > 0.25	47 (57%)	6 (60%)	0.871
CRP	123 (53–194)	77 (15–142)	0.231
proADM	0.76 (0.56–1.04)	0.85 (65–1.25)	0.360
Day 3
PCT	0.12 (0.06–0.42)	0.13 (0.09–0.63)	0.794
PCT ≤ 0.25	51 (66%)	7 (78%)	0.484
PCT ≤ 0.25 or PCT decline ≥80%	62 (80%)	8 (89%)	0.542
proADM	0.56 (0.47–0.76)	0.59 (0.53–0.74)	0.679
Long treatment (n = 157)	n = 147	n = 10
At presentation
PCT	0.48 (0.15–1.49)	0.48 (0.09–3.13)	0.826
PCT > 0.25	89 (60%)	6 (60%)	0.973
CRP	119 (52–224)	181 (37–263)	0.531
proADM	0.98 (0.67–1.44)	0.86 (0.62–1.21)	0.495
Day 3
PCT	0.22 (0.08–1.08)	0.08 (0.04–0.72)	0.358
PCT ≤ 0.25	71 (56%)	5 (56%)	0.984
PCT ≤ 0.25 or PCT decline ≥80%	82 (65%)	6 (67%)	0.899
proADM	0.74 (0.53–1.03)	0.74 (0.47–1.02)	0.609

Data presented as median (IQR) or number (%)

CRP at presentation missing: n = 41 in short treatment and n = 41 in long treatment